Recent Quotes (30 days)

You have no recent quotes
chg | %

BioTime, Inc.  

(Public, NYSEAMERICAN:BTX)   Watch this stock  
Find more results for BTX
2.50
+0.04 (1.63%)
Nov 17 - Close
NYSEAMERICAN real-time data - Disclaimer
Currency in USD
Range 2.46 - 2.59
52 week 2.19 - 3.96
Open 2.46
Vol / Avg. 265,079.00/431,635.00
Mkt cap 317.16M
P/E 5.83
Div/yield     -
EPS 0.43
Shares 126.87M
Beta 2.01
Inst. own 39%
Dec 6, 2017
BioTime Inc at LD Micro One-on-One Meetings Main Event Add to calendar
Nov 15, 2017
BioTime Inc at Jefferies Global Healthcare Conference
Nov 9, 2017
Q3 2017 BioTime Inc Earnings Call - Webcast
Nov 9, 2017
Q3 2017 BioTime Inc Earnings Release
Oct 5, 2017
BioTime Inc at Alliance for Regenerative Medicine (ARM) Stem Cell Meeting on the Mesa
Sep 27, 2017
BioTime Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 26, 2017
BioTime Inc at Ladenburg Thalmann Healthcare Conference
Sep 12, 2017
BioTime Inc at Rodman & Renshaw Global Investment Conference
Sep 5, 2017
BioTime Inc at LD Micro Summit
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 828.55% 314.38%
Operating margin -729.38% -167.47%
EBITD margin - -915.25%
Return on average assets 27.02% 15.70%
Return on average equity 30.68% 46.36%
Employees 100 -
CDP Score - -

Address

1010 Atlantic Ave Ste 102
ALAMEDA, CA 94501-1147
United States - Map
+1-510-5213390 (Phone)
+1-510-5213389 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology. Its clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its facial aesthetics product, Renevia, is a potential treatment for facial lipoatrophy. It is in a pivotal clinical trial in Europe to assess its safety and efficacy in restoring normal skin contours in patients whose subcutaneous fat, or adipose tissue, has been lost due to the use of certain drugs often used to treat patients with human immune virus. OpRegen is its lead product for ophthalmological disorders. It is a suspension of retinal pigment epithelial cells that are derived from pluripotent stem cells.

Officers and directors

Alfred D. Kingsley Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Aditya P. Mohanty Co-Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Michael D. West Ph.D. Co-Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Russell L. Skibsted Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Judith Segall Vice President, Secretary
Age: 61
Bio & Compensation  - Reuters
Stephana Eilene Patton Ph.D., J.D. General Counsel
Age: 46
Bio & Compensation  - Reuters
Deborah J. Andrews Independent Director
Age: 59
Bio & Compensation  - Reuters
Neal C. Bradsher Independent Director
Age: 51
Bio & Compensation  - Reuters
Stephen C. Farrell CPA Independent Director
Age: 52
Bio & Compensation  - Reuters
Michael H. Mulroy Independent Director
Age: 51
Bio & Compensation  - Reuters